Shorted
Oncosil Medical logo
OSL
Pharmaceuticals, Biotechnology & Life Sciences

Oncosil Medical

Short interest
0.00%
0.00 pp 30d
as of 7 Oct 2026
Reported shorts
66
Shares on issue
36.704M

Oncosil Medical (OSL) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
9 Sept

OncoSil Medical Reframes the Execution Pathway Case (ASX:OSL)

Highlights OncoSil Medical has placed execution pathway at the centre of current trading focus through its recent filing. The update directs attention toward funding access, milestone delivery and trading liquidity without removing the need for careful evidence review. Market reading depends on delivery quality, clear reporting and alignment between strategy, funding and operating conditions. OncoSil Medical (ASX:OSL) has drawn attention during the latest completed Australian market session a...

Continue reading
Kalkine
Neutral
5 Aug

Top Healthcare Stocks to Watch: Why Is OncoSil Medical (ASX:OSL) in Focus?

Highlights OncoSil Medical has issued a fresh update on Saudi regulatory approval. The announcement introduces a specific company development to the news cycle. Follow-up disclosure will show how the development translates into delivery. OncoSil Medical (ASX:OSL) is in focus this week after an announcement on Saudi regulatory approval, giving Australian readers a concrete new development to assess within the current market setting. What the announcement changes The announcement is most useful...

Continue reading
Kalkine
Neutral
5 Aug

Can OncoSil Medical (ASX:OSL) Advance Commercialisation Through Manufacturing Validation Completion?

Highlights manufacturing validation completion is the immediate operational question for OncoSil Medical. The update is best assessed against the business model and stated priorities. The next reporting point will add evidence on execution. OncoSil Medical (ASX:OSL) is in focus this week after an announcement on manufacturing validation completion, giving Australian readers a concrete new development to assess within the current market setting. The execution question This is a business-execut...

Continue reading
Kalkine
Neutral
17 July

OncoSil Medical Executes 532 Options at AUD $0.90, Boosting Total Shares to 30.89 Million

OncoSil Medical Ltd (ASX: OSL), a medical device company listed on the Australian Securities Exchange, has applied for quotation of 532 fully paid ordinary shares following the exercise of options set to expire on 30 June 2027. The option exercise took place on 17 July 2026 at an issue price of AUD $0.90 per share. This transaction reflects ongoing capital management efforts by the company and increases the total issued ordinary shares to approximately 30.89 million after quotation. Key Highli...

Continue reading
Kalkine
Positive
13 July

OncoSil Medical Expands Local Manufacturing for the Next Phase of Growth

Highlights Local manufacturing capability reaches a major milestone. Validation strengthens production quality and supply confidence. Commercial rollout moves closer with regulatory progress. OncoSil Medical has completed an important manufacturing validation milestone, reinforcing its local production capabilities and supporting its broader commercial expansion strategy. The development is expected to strengthen operational efficiency, supply reliability,...

Continue reading
Kalkine
Neutral
12 June

Why OncoSil’s Quiet Update Could Signal a Defining Period Ahead

Highlights OncoSil Medical highlighted a potentially milestone-rich second half of the year following recent regulatory and clinical progress. Key areas of focus include US regulatory advancement, clinical trial outcomes, and manufacturing expansion. Commercial adoption remains the most important measure of long-term success despite recent achievements. OncoSil enters a crucial phase as regulatory progress, clinical data, manufacturing expansion, and commercial adoption become the central the...

Continue reading